Activation of caspase-3 and apoptosis in cerebellar granule cells.
Caspase-3 activity increased dramatically in cytosolic extracts of rat cerebellar granule cells exposed to apoptotic conditions (basal medium Eagle (BME) containing 5 mM K+ without serum) when assayed with Ac-DEVD-amc, but not with Ac-YVAD-afc, a preferred substrate for caspase-1. This provided a basis to examine relationships between enzyme activity and cell viability for purposes of selecting an optimal time for comparing neuroprotective agents or strategies. Exposure of neurons to an apoptotic medium containing 5 mM K+ in absence of serum led to a rapid 5- to 10-fold increase in caspase-3 within 2-4 hr but without significant cell loss, or morphological alterations. Exposure to apoptotic medium followed by replacement with maintenance medium containing 25 mM K+ and serum led to a rapid fall in caspase-3 and prevention of cell death. This strategy was not effective after 13 hr exposure despite a large fall in enzyme activity. These temporal changes infer systems for rapid enzyme turnover and/or activation of cytoplasmic components linked to later DNA degradation. The effects of cycloheximide point to requirements for protein synthesis, and those of Glu exclude a caspase-3 dependent pathway for necrotic cell damage. Brief treatment with 10 microM LIGA20, an anti-necrotic agent, also attenuated cell loss and caspase-3 activity, indicating a broad spectrum of neuroprotection. Rapid and long-lasting effects, together with its biophysical properties, suggest that this semisynthetic ganglioside acted upstream at or near a membrane site. As such, gangliosides provide useful agents to further probe pathways relevant to neuronal death in culture.
Marks
N
N
Nathan S. Kline Institute for Psychiatric Research, Center for Neurochemistry and Neurobiology, Orangeburg, New York 10962, USA. marks@nki.rfmh.org
Berg
M J
MJ
Guidotti
A
A
Saito
M
M
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D053148:Caspase 3; D020169:Caspases; D002470:Cell Survival; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology*; D003374:Coumarins / Q000378:metabolism; D016895:Culture Media, Serum-Free; D003513:Cycloheximide / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004789:Enzyme Activation; D005677:G(M1) Ganglioside / Q000031:analogs & derivatives / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology; D009842:Oligopeptides / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology
C112287:Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin; D003374:Coumarins; D016895:Culture Media, Serum-Free; D018696:Neuroprotective Agents; D009842:Oligopeptides; D011500:Protein Synthesis Inhibitors; C086919:LIGA 20; D005677:G(M1) Ganglioside; D003513:Cycloheximide; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D003546:Cysteine Endopeptidases; D013110:Sphingosine; D011188:Potassium